



ASX Code: SIP

25 June 2010

ASX ANNOUNCEMENT

Sigma agrees to extend Aspen exclusivity period

On 31 May 2010, Sigma announced that it had entered into a confidentiality agreement with Aspen Pharmacare Holdings Limited ("**Aspen**") pursuant to which Aspen would be provided with due diligence information on Sigma.

As part of that agreement, Aspen was granted limited exclusivity by Sigma for four weeks. In response to a request from Aspen, Sigma has agreed to extend the exclusivity period to 5 July 2010 to enable Aspen to complete its due diligence review.

Sigma continues to recommend that shareholders take no action at this time. The due diligence process being undertaken by Aspen may or may not result in a formal proposal or a recommendation by the Board.

Sue Morgan-Dethick
General Counsel & Company Secretary

SIGMA PHARMACEUTICALS LIMITED
ABN 15 088 417 403

Locked Bag 268 (96 Merrindale Drive) Croydon Victoria 3136 Australia
Telephone: (+61-3) 03-9839 2800 Facsimile: (+61-3) 03-9839 2811